The merger vote is the key catalyst on July 8. Monitor for ISS/Glass Lewis recommendations and any additional shareholder lawsuits that could delay closing. The supplemental disclosures are unlikely to change the vote outcome given management's ~5.5% ownership and the premium offer.
Price Chart
Executive Summary
Catalyst Pharmaceuticals filed a DEFA14A supplement to its definitive proxy statement for the July 8, 2026 special meeting to vote on the $31.50/share all-cash acquisition by Angelini Pharma. The supplement voluntarily adds disclosures regarding a shareholder lawsuit (Seaward v. Catalyst) alleging inadequate proxy disclosures, additional background on merger negotiations with multiple parties, and financial projections. The company believes the lawsuit is without merit and the supplemental disclosures aim to mitigate litigation risk.
Key Facts
- Special meeting to vote on merger with Angelini Pharma scheduled for July 8, 2026; record date June 3, 2026.
- One shareholder lawsuit filed June 10, 2026 in N.D. Illinois (Seaward v. Catalyst) alleging inadequate proxy disclosures; company believes claims are without merit.
- Supplemental disclosures include December 2025 and March 2026 financial projections for FIRDAPSE, AGAMREE, and FYCOMPA revenue through 2035.
- CEO Richard Daly proposed retention terms: $875,000 base salary, 80% annual bonus target, 2x base+target retention bonus (75% at year 1, 25% at year 2) with non-compete and waiver of Good Reason rights.
- Required vote: majority of outstanding shares (61,208,729 votes); directors and officers beneficially own ~5.5% of shares.
- Merger consideration is $31.50 per share in cash, with all unvested options and RSUs accelerating and cashing out.
Financial Impact
No new financial impact; merger consideration remains $31.50/share. Supplemental projections show 2026 total revenue of $669M (Dec 2025) or $635M (Mar 2026).
Risk Factors
- Shareholder lawsuit could seek injunction delaying or blocking the merger, though company believes claims are without merit.
- Additional demand letters or lawsuits may be filed before the special meeting.
- Required vote threshold (majority of outstanding shares) means abstentions and broker non-votes count as 'against'.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-290840 |
| Document: 0001193125-26-290840-index-headers.html | 0001193125-26-290840 |
| Document: 0001193125-26-290840-index.html | 0001193125-26-290840 |
| Document: 0001193125-26-290840.txt | 0001193125-26-290840 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 22, 2026 5w ago | Institutional Cluster | — | awaiting T+5 | — | — |
Jul 24, 2026 9w ago | 15-12G | $31.49 awaiting T+5 | awaiting T+5 | — | — |
Jul 17, 2026 11w ago | EFFECT | $31.49 $31.49 | · 0.00% | ▼ −0.59% | — |
Jul 15, 2026 11w ago | 25-NSE | $31.49 $31.49 | · 0.00% | ▼ −0.98% | — |
Jul 8, 2026 12w ago | 8-K | $31.47 $31.49 | ▲ +0.06% | ▲ +0.20% | — |
Jun 30, 2026 13w ago | DEFA14A | $31.44 $31.49 | ▲ +0.16% | ▼ −0.10% | — |
Jun 30, 2026 13w ago | 8-K | $31.44 $31.49 | ▲ +0.16% | ▼ −0.10% | — |
May 28, 2026 18w ago | PREM14A | $31.23 $31.28 | ▲ +0.16% | ▲ +0.45% | — |
May 12, 2026 20w ago | DEFA14A | $31.14 $31.23 | ▲ +0.29% | ▲ +0.21% | — |
May 11, 2026 20w ago | Press Release | $31.14 $31.23 | ▼ −0.29% | ▼ −0.21% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access